Loading organizations...

§ Private Profile · San Francisco, CA, USA
Biotech company providing Delve Detect, a metagenomic next-generation sequencing platform for infectious disease diagnosis.
San Francisco, California-based Delve Bio is a biotechnology company that transitions metagenomic next-generation sequencing technology from academic research laboratories into practical clinical settings for infectious disease diagnostics. The organization provides a specialized genomic testing platform called Delve Detect, which analyzes cerebrospinal fluid to accurately identify more than 68,000 distinct pathogens in patients suffering from serious central nervous system infections. This diagnostic tool, which officially launched commercially in 2024, replaces traditional iterative testing methods by delivering comprehensive pathogen identification results and expert consultation support to clinicians within a strict 48-hour turnaround time. The enterprise is financially backed by several prominent institutional venture capital firms, securing funding from recognizable industry investors including Perceptive Xontogeny Venture Fund II, Section 32, and Google Ventures. The company was founded by academic researchers Charles Chiu, Joe DeRisi, Michael Wilson, and Matthew Meyerson.
Delve Bio has raised $35.0M across 1 funding round.
Delve Bio has raised $35.0M in total across 1 funding round.
Delve Bio has raised $35.0M in total across 1 funding round.
Delve Bio's investors include Perceptive Advisors, Google Ventures, Section 32.
Delve Bio has raised $35.0M across 1 funding round. Most recently, it raised $35.0M Series A in June 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2023 | $35M Series A | Perceptive Advisors | GV, Section 32 | Announced |
Delve Bio is a biotechnology company developing precision diagnostics for infectious diseases through metagenomic next-generation sequencing (mNGS) technology.[1][2][3] Its flagship product, Delve Detect, performs comprehensive pathogen detection—including bacteria, fungi, parasites, and viruses—with a single test and 48-hour turnaround, analyzed via the proprietary Delve Decide bioinformatics pipeline, serving labs, clinicians, and hospitals to diagnose routine and rare infections.[1][3][4][6] This addresses the limitations of traditional "guess and test" methods that rely on targeted panels, reducing prolonged hospital stays and inappropriate treatments while enabling faster, hypothesis-free identification.[2][3] Founded in 2022 and headquartered in San Francisco, the company has raised $35M in Series A funding from investors like Google Ventures (GV), Section 32, and Perceptive Xontogeny Venture Fund II, showing strong early momentum with recent data on viral subtyping presented in May 2025.[1][3][4]
Delve Bio was founded in 2022 by renowned experts in genomics and infectious diseases: Drs. Charles Chiu, Joe DeRisi, Michael Wilson, Pardis Sabeti, and Matthew Meyerson, who brought decades of pioneering research from institutions like UCSF.[1][3][4] The idea emerged from their work translating lab-based mNGS—initially developed for research—into clinical tools, highlighted by pivotal moments like Joe DeRisi's 2016 TEDMED talk on next-gen sequencing for mysterious infections, New York Times coverage as "The Disease Detective," and research by DeRisi and Wilson on treating rare brain-eating amoeba infections.[2] Brad Murray serves as co-founder and CEO, driving commercialization to bring this "game-changing" technology from academia to clinics, backed by exclusive UCSF licensing and top investors.[3][4][5]
Delve Bio stands out in infectious disease diagnostics through these key strengths:
Delve Bio rides the genomics revolution in diagnostics, extending oncology and rare disease successes to infectious diseases long overlooked despite their global burden.[3][5] Timing is ideal post-pandemic, as rising antimicrobial resistance, complex infections, and demands for rapid, comprehensive testing amplify mNGS's value amid market forces like hospital efficiency pressures and pathogen unpredictability.[2][3][4] By commercializing UCSF-honed tech, it influences the ecosystem—partnering with leading institutions, attracting elite VC (e.g., GV), and setting standards for "test once and know," potentially shortening diagnostics from weeks to days and curbing outbreaks.[1][2][4]
Delve Bio is poised to make mNGS the standard for infectious disease testing, with expansion into more viral subtyping, broader hospital adoption, and platform enhancements driving growth beyond its $35M Series A.[1][4] Trends like AI-augmented bioinformatics, personalized medicine, and global health threats will accelerate its trajectory, evolving its influence from niche diagnostics to ecosystem-wide impact—echoing how its founders' research already saved lives from rare pathogens.[2][3] As precision medicine scales, Delve could redefine "what's next" for clinicians facing the unknown, minimizing humanity's pathogen toll.[2][4]